Trials / Completed
CompletedNCT00163150
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 128 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin |
Timeline
- Start date
- 2003-06-01
- Completion
- 2006-02-01
- First posted
- 2005-09-13
- Last updated
- 2021-02-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00163150. Inclusion in this directory is not an endorsement.